CMS granted coverage for NeoGenomics' PanTracer LBx, a blood‑based comprehensive genomic profiling assay intended to inform therapy selection and clinical trial enrollment for advanced solid tumors. The coverage decision removes a major reimbursement barrier for widespread clinical adoption of circulating tumor DNA (ctDNA) assays in oncology care, potentially accelerating testing uptake at community and academic centers. Reimbursement by CMS typically influences private payers; labs and oncologists will monitor coverage details and coding guidance that determine patient access.